The healthcare company is moving to Phase 2 trials of its imaging technology that’s helping covid patients.
The post 4DMedical (ASX:4DX) share price is lifting on its covid-related technology appeared first on The Motley Fool Australia. –
The 4DMedical Ltd (ASX: 4DX) share price is in the green this morning. That’s after the healthcare company announced it will move on to phase-2 clinical trials for its respiratory scanning technology.
At the time of writing, shares in the company are trading for $1.62 – up 1.57% after earlier hitting $1.65. The ASX All Ordinaries Index (ASX: XAO), meanwhile, is 0.75% lower.
Let’s take a closer look at today’s news.
4DMedical share price rises on latest announcement
In a statement to the ASX, 4DMedical says it will progress to phase 2 clinical trials for its XV Lung Ventilation Analysis Software (XV LVAS) – a respiratory imaging platform. The trials are being completed in partnership with I-MED Radiology Network (I-MED).
The company says its technology provided “valuable insights” into a plethora of respiratory diseases, including asthma, silicosis, and long-COVID. Long-COVID refers to the continuation of symptoms felt by some covid patients long after acquiring the infection.
Phase one trials were conducted in Victoria. 4DMedical says the next stage will be completed in a different state “over the remainder of the year”. The company is still looking into a commercial partnership with I-MED going forward.
Investors clearly love today’s announcement, judging by the rising 4DMedical share price.
4DMedical founder and CEO Andreas Fouras said:
We are very excited to be conducting a clinical pilot with I-MED – a leader of pioneering new medical imaging technologies – to provide doctors and patients with improved insight into their lung health. Phase One of the clinical pilot was an overwhelming success with radiologists and patients reporting strong positive feedback. Although the partnership is not generating revenue at this stage, we aim to secure a commercial XV LVAS contract with I-MED provided that Phase Two is successful.
I-MED General Manager of external partnerships and government relations Mark Simpson added
Patients involved in the Phase One pilot overwhelmingly reported a positive experience. Beyond the technical success of the program, this important comfort and compliance metric shows we can adopt such transformative technologies without detriment to patient satisfaction, sustaining our ongoing commitment to outstanding patient care.
4DMedical share price snapshot
Over the past12 months, the 4DMedical share price has increased around 14%. It’s underperformed the All Ords Index by approximately 12 percentage points in that time.
4D Medical has a market capitalisation of around $342 million.
Should you invest $1,000 in 4DMedical right now?
Before you consider 4DMedical, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and 4DMedical wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of August 16th 2021
Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.